Blar i NTNU Open på forfatter "Vasan, Ramachandran S."

Viser treff 1-2 av 2

    • Aptamer-Based Proteomic Platform Identifies Novel Protein Predictors of Incident Heart Failure and Echocardiographic Traits 

      Nayor, Matthew; Short, Meghan I.; Rasheed, Humaira; Lin, Honghuang; Jonasson, Christian; Yang, Qiong; Hveem, Kristian; Felix, Janine F.; Morrison, Alanna C.; Wild, Philipp S.; Morley, Michael P.; Cappola, Thomas P.; Benson, Mark D.; Ngo, Debby; Sinha, Sumita; Keyes, Michelle J.; Shen, Dongxiao; Wang, Thomas J.; Larson, Martin G.; Brumpton, Ben Michael; Gerszten, Robert E.; Omland, Torbjørn; Vasan, Ramachandran S. (Peer reviewed; Journal article, 2020)
      Abstract Background: We used a large-scale, high-throughput DNA aptamer-based discovery proteomic platform to identify circulating biomarkers of cardiac remodeling and incident heart failure (HF) in community-dwelling ...

    • Loss-of-function genomic variants highlight potential therapeutic targets for cardiovascular disease 

      Nielsen, Jonas Bille; Rom, Oren; Surakka, Ida; Graham, Sarah E.; Zhou, Wei; Roychowdhury, Tanmoy; Fritsche, Lars; Gagliano Taliun, Sarah; Sidore, Carlo; Liu, Yuhao; Gabrielsen, Maiken Elvestad; Skogholt, Anne Heidi; Wolford, Brooke; Overton, William; Zhao, Ying; Chen, Jin; Zhang, He; Hornsby, Whitney E.; Acheampong, Akua; Grooms, Austen; Schaefer, Amanda; Zajac, Gregory J.M.; Villacorta, Luis; Zhang, Jifeng; Brumpton, Ben Michael; Løset, Mari; Rai, Vivek; Lundegaard, Pia R.; Olesen, Morten S.; Taylor, Kent D.; Palmer, Nicholette D.; Chen, Yii-Der; Choi, Seung Hoan; Lubitz, Steven A.; Ellinor, Patrick T.; Barnes, Kathleen C.; Daya, Michelle; Rafaels, Nicholas; Weiss, Scott T.; Lasky-Su, Jessica; Tracy, Russell P.; Vasan, Ramachandran S.; Cupples, L. Adrienne; Mathias, Rasika A.; Yanek, Lisa R.; Becker, Lewis; Holmen, Oddgeir Lingaas; Åsvold, Bjørn Olav; Willer, Christen; Hveem, Kristian (Peer reviewed; Journal article, 2020)
      Pharmaceutical drugs targeting dyslipidemia and cardiovascular disease (CVD) may increase the risk of fatty liver disease and other metabolic disorders. To identify potential novel CVD drug targets without these adverse ...